Predictive Accuracy of HeartMate 3 Risk Score After the Heart Transplant Allocation Change.

IF 3.1 3区医学 Q2 ENGINEERING, BIOMEDICAL

ASAIO Journal Pub Date : 2024-11-06 DOI:10.1097/MAT.0000000000002343

Justin D Vincent, Alyssa Ramsay, David S Lambert, Elena Deych, Ana María Pico, Erin Coglianese, Justin M Vader, Bin Q Yang

引用次数: 0

Abstract

The HeartMate 3 risk score (HM3RS) was developed from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) clinical trial to predict 1 and 2 year mortality after left ventricular assist device implantation. However, it has not been validated in a real-world population, especially after the heart transplant allocation system change on October 18, 2018. In this multicenter retrospective analysis, we found that HM3RS did not predict 1 and 2 year outcomes in the contemporary era, highlighting the need to revise this risk prediction tool in the real-world setting.

查看原文本刊更多论文

心脏移植分配变化后 HeartMate 3 风险评分的预测准确性。

HeartMate 3风险评分（HM3RS）是根据MagLev技术在接受HeartMate 3机械循环支持治疗患者中的多中心研究（MOMENTUM 3）临床试验开发的，用于预测左心室辅助装置植入术后1年和2年的死亡率。然而，该技术尚未在现实世界人群中得到验证，尤其是在 2018 年 10 月 18 日心脏移植分配系统变更之后。在这项多中心回顾性分析中，我们发现 HM3RS 在当代并不能预测 1 年和 2 年的预后，这凸显了在真实世界环境中修订这一风险预测工具的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ASAIO Journal 医学-工程：生物医学

CiteScore

6.60

自引率

7.10%

发文量

651

审稿时长

4-8 weeks

期刊介绍： ASAIO Journal is in the forefront of artificial organ research and development. On the cutting edge of innovative technology, it features peer-reviewed articles of the highest quality that describe research, development, the most recent advances in the design of artificial organ devices and findings from initial testing. Bimonthly, the ASAIO Journal features state-of-the-art investigations, laboratory and clinical trials, and discussions and opinions from experts around the world. The official publication of the American Society for Artificial Internal Organs.